Alkermes plc
ALKS
Kedudukan dalam Saham
#2637
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Harga Saham
$43.05
Modal Pasaran
$7.22B
Perubahan (1 hari)
4.43%
Perubahan (1 tahun)
42.25%
Negara
IE
Perdagangan Alkermes plc (ALKS)
Kategori
Healthcare
Bilangan saham terbitan bagi Alkermes plc (ALKS)
Bilangan saham terbitan setakat June 2026: 166.61M
Menurut laporan kewangan terkini dan harga saham Alkermes plc, bilangan saham terbitan semasa ialah 166.61M. Pada akhir December 2023, syarikat mempunyai 166.22M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Alkermes plc (ALKS) dari 2000 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 166.61M | 0.74% |
| 2024 | 165.39M | -0.50% |
| 2023 | 166.22M | 1.52% |
| 2022 | 163.74M | 1.74% |
| 2021 | 160.94M | 1.35% |
| 2020 | 158.80M | 1.12% |
| 2019 | 157.05M | 1.25% |
| 2018 | 155.11M | 1.11% |
| 2017 | 153.42M | 1.27% |
| 2016 | 151.48M | 1.53% |
| 2015 | 149.21M | 2.71% |
| 2014 | 145.27M | 10.30% |
| 2013 | 131.71M | 0.00% |
| 2012 | 131.71M | 14.83% |
| 2011 | 114.70M | 19.97% |
| 2010 | 95.61M | 0.81% |
| 2009 | 94.84M | -0.34% |
| 2008 | 95.16M | -5.54% |
| 2007 | 100.74M | 1.51% |
| 2006 | 99.24M | 9.03% |
| 2005 | 91.02M | 1.03% |
| 2004 | 90.09M | 9.76% |
| 2003 | 82.08M | 27.52% |
| 2002 | 64.37M | 1.10% |
| 2001 | 63.67M | 14.21% |
| 2000 | 55.75M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 52.39% |
US
|
|
| 396.00M | 137.68% |
US
|
|
| 478.91M | 187.44% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -62.68% |
NL
|
